Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Recurrence 2Peritoneal Neoplasms 2Lung Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Radiation Pneumonitis 1Patients With Any Advanced Solid Tumors 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Mesothelioma, Malignant 1Melanoma, Cutaneous Malignant 1Malignant Solid Tumour 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1

Interventions

Paclitaxel 4Carboplatin 4Pemetrexed 2Palliative Care 2Gemcitabine 2temsirolimus 1rucaparib 1pembrolizumab 1niraparib 1nintedanib 1nilotinib 1liposomal doxorubicin 1fosaprepitant 1atezolizumab 1argatroban 1Topotecan 1Thrombopoietin 1Palonosetron 1Ocoxin 1Laparoscopy 1Heparin, Low-Molecular-Weight 1Filgrastim 1Electrocardiography 1Educational Status 1Dexamethasone 1Darbepoetin alfa 1Cognitive Behavioral Therapy 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Genital Neoplasms, Female × nintedanib × Clear all
NCT02182245 2025-01-23

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Boehringer Ingelheim

Phase 1 Completed
22 enrolled

Genital Neoplasms, Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡